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TNFa is a potent mediator ofinflammation (1, 2) . Its actions are believed to re-
sult from binding to a single class of receptors (TNFctR) on the surface of a wide
variety of cells (3-6) . In principle, agents that affect the number or affinity ofTNF-
c1R, such as IFN- ,y (7-9), LPS (10), or activators of protein kinase C or A (11-14),
may modulate some of TNF-a's biologic effects .
Among antineoplastic and nonsteroidal antiinflammatory drugs are compounds,
such as colchicine, nocodazole, vincristine, vinblastine, and podophyllotoxin, which
bind tubulin and inhibit its polymerization. Disassembly of cytoplasmic microtu-
bules (MT) 1 by these agents causes mitotic arrest in dividing cells, suggesting a
mechanism of action for their antineoplastic effects . It is less clear how colchicine
exerts antiinflammatory actions in conditions as diverse as gout, familial Mediterra-
nean fever, cirrhosis, pericarditis, and Behcet's disease . Possible mechanisms include
inhibition of the ability ofpolymorphonuclear leukocytes to migrate (15), degranu-
late (16), or translocate 5-lipoxygenase (17) . We have observed that exposure ofmu-
rine and human macrophages and human umbilical vein endothelial cells to
micromolar concentrations of five differentMT depolymerizing agents resulted in
a rapid decrease in surface TNFciR . MT appeared to be required either for the
synthesis ofTNFaR or for their translocation to the plasma membrane . This effect
may contribute to the antiinflammatory actions ofMT depolymerizing agents .
Volume 171 March 1990 715-727
Materials and Methods
Materials .
￿
Human rTNFce (4 .1 x 107 U/mg protein), murine rINFy (5.2 x 10 7 U/mg
protein) and antiserum 15E against murine TNFa (6.4 x 105 neutralizing units/ml) were
kindly provided by Genentech, Inc . (South San Francisco, CA) . Na1211 (carrier-free) was
from the Radiochemical Center, Amersham, UK . Thioglycollate broth (Brewer) was obtained
from Difco Laboratories (Detroit, MI) . The following were from Sigma Chemical Co. (St .
Louis, MO) : colchicine, fl-lumicolchicine, y-lumicolchicine, nocodazole, vinblastine, vin-
cristine, podophyllotoxin, cytochalasin B, dihydrocytochalasin B, cytochalasin E, PGE,,
dibutyryl-cyclic adenosine monophosphate, indomethacin, ibuprofen, acetylsalicylic acid, and
cycloheximide .
Address correspondence to Dr . A . H . Ding, Cornell University Medical College, 1300 York Avenue,
Box 57, New York, NY 10021 .
' Abbreviation used in this paper . MT, microtubule.
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Cell Culture.
￿
Murine macrophages were washed from the peritoneal cavities offemale CDl
mice (Charles River Breeding Laboratories, Wilmington, MA). Where indicated, mice were
injected intraperitoneally with 2 ml of thioglycollate broth (Brewer, 4%) 4 d earlier as de-
scribed (18). Adherent monolayers were obtained by plating 8 x 105 cells per well in 24-well
plastic trays or 2 x 105 cells per well in 96-well plastic trays in RPMI 1640 (KC Biological,
Inc., Lenexa, KS) containing 10% heat-inactivated FCS (HyClone Laboratories, Logan, UT).
Monolayers were maintained at 37°C in 5% C02/95 17o air for 1-4 d before the experiments.
Human macrophages were allowed to mature from peripheral blood monocytes in Teflon
beakers as described (19). Second-passage human umbilical vein endothelial cells were the
gift ofDr. EricJaffe (Cornell University Medical College, New York, NY) and were prepared
as described (20). Human polymorphonuclear leukocytes (PMN) were isolated from
heparinized venous blood on Neutrophil Isolation Medium (Los Alamos Diagnostics, Los
Alamos, NM) as described (21).
Iodination ofrTNF-a and rIFN-y.
￿
Human rTNFa and murine rIFN-y were iodinated ac-
cording to the method o£ Aggarwal et al. (22), and stored at VC for no longer than 6 wk.
In brief, 100 p.l of 0.1 M phosphate buffer (pH 7 .4) was added to a glass tube coated with
5 lAg of Iodogen (Pierce Chemical Co., Rockford, IL) and incubated with 1 mCi of Na'25I
for 10 min at 4oC. The mixture was then transferred to a tube containing 10 Rg of rTNFa
or rIFN-y for 10 min at 4°C. The reaction was stopped by addition of one drop of 1 M KI.
Iodinated material was separated from free iodide by filtration through a PD-10 column (Phar-
macia Fine Chemicals, Piscataway, NJ) that had been equilibrated with 0.1 M phosphate
(for rTNF-a) or 20 mM Tris buffer (for rIFN-y), both containing 0.1% gelatin, pH 7.4.
'251-rTNFa had a specific activity of -300 Ci/mmol monomer, and migrated as a single
band with an apparent molecular mass of -16 kD on an 1117o polyacrylamide gel under non-
reducing conditions. '21I-rIFN-y had a specific activity of -100 Ci/mmol monomer. Both
cytokines retained their ability to activate resident mouse peritoneal macrophages for en-
hanced H202 release (18).
Receptor Binding Assay.
￿
Cell monolayers in 24-well trays were overlaid with 0.3 ml per well
ofbinding buffer (HBSScontaining 10% FCS) and incubated with indicated concentrations
of 1251-rTNFot in the presence or absence of a 100-fold excess of unlabeled rTNFa . After
3-4 h at 4oC, binding buffer was removed and the monolayers rinsed four times with ice
cold 0.9% NaCl. Cells were solubilized in 0.3 ml of 0.3 N NaOH and radioactivity deter-
mined in a gamma counter (Packard InstrumentCo., Downers Grove, IL). Binding to human
PMN in suspension was carried out as described (10). Nonspecific binding was <15% of the
total and was subtracted to calculate specific binding. When the effects of drugs were exam-
ined, the cells were incubated with the drugs for 1 h at 37'C before the binding assay.
To assay IFN-y receptor (IFN-yR), the above method was modified to reduce sticking of
radiolabeled rIFN-y to plastic: (a) Binding was carried out at room temperature instead of
4oC. (b) Binding buffer was changed to RPMI 1640 containing 50 MM Hepes, 10 mM
NaN3, and 1% (wt/vol) BSA. (c) Cell-bound "'I-rIFN-y was eluted with 50 mM glycine in
saline, pH 3, at 4oC for 5 min (in contrast, '251-rIFN-y bound to plastic can be eluted with
NaOH). Nonspecific binding was <l0olo of the total, and was subtracted to calculate specific
binding.
Hydrogen Peroxide Release.
￿
H202 secretion was measured fluorometrically by the horse-
radish peroxidase-catalyzed oxidation offluorescent scopoletin to a nonfluorescent product,
as described in detail (23). The protein content of cells adherent at the start of the assay in
each well was measured by the method of Lowry et al. (24) with BSA as a standard. Specific
release was calculated after subtracting H202 and protein values from the cell-free wells.
Measurement of LPS .
￿
LPS contamination of reagents was monitored by a chromogenic
limulus amebocyte lysate test (WhittakerBioproducts, Inc., Walkersville, MD) with a sensi-
tivity of -10 pg/ml.
Results
Decreased 1251-rTNFa Binding to Macrophages afterPreincubation with MT Depolymerizing
Agents.
￿
It was established previously that murine macrophages bind "'I-labeledhuman rTNFa specifically and reversibly (10). Preexposureof macrophagesto 3 IM
nocodazole for 1 h at 37 °C inhibited the subsequent binding of 1251-rTNFa at 4°C
(Fig. 1). Scatchardanalysis ofthedata indicatedthat nocodazole affected the numbers
of receptor sites rather than their affinity (Fig. 1, inset). TNFceR of human macro-
phages were reduced in a similar fashion in response to colchicine in two experi-
ments (not shown). Mouse macrophages were used to characterize this effect further.
Pretreatment with threeotherMT depolymerizing agents, vincristine, vinblastine,
and podophyllotoxin, also diminished subsequent 1251-rTNFa binding in a concen-
tration-dependent manner (Fig. 2). In contrast, (3- andy-lumicolchicine, which do
not depolymerize MT, did not suppress binding of 1251-rTNFa. The microfilament-
disrupting agents cytochalasin B, dihydrocytochalasin B, and cytochalasin E had
little or no effect (Table I). As a control, the effect of colchicine on IFN-,YR, another
cytokine receptor on the macrophage surface, wastested underthe same conditions.
Binding of rIFN-y was not affected by colchicine or nocodazole (Table I). This sug-
gested that theeffects of colchicine and nocodazole on TNFaR did not result from
nonspecific toxicity.
Downregulation of TNFaR by MTdepolymerizing agents depended on temper-
ature. In contrast to results at 37°C, preexposure of macrophages to 10,M colchi-
cine or 10 tLM nocodazole at 4°C caused no detectable change in 1251-rTNFa
binding. Nor did colchicine or nocodazole compete with TNFa binding sites at
4°C (not shown).
Recovery of TNFciR afterexposure to MTdepolymerizing agents correlated with
thereversibility of theirbinding to tubulin. Aftera 1-h exposure to 10 ,,Mcolchicine
or 3 1.M nocodazole, macrophages were incubated in drug-free medium forvarious
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FIGURE 1.
￿
Decreased surface
TNFciR after treatment with
nocodazole. Indicatedamounts
of 1251-rTNFa were added to
murine peritoneal macrophages
pretreated with (A)or without
(")3 pM nocodazole for 1 hat
37°C. Binding was assayed as
described. (Inset)Scatchardanal-
ysis oftheequilibrium binding
data. The results are meansfor
triplicates.718
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periods before the 1251-rTNFa binding assay (Fig. 3). Colchicine binds irrevers-
ibly to tubulin (25). The ability ofmacrophages to bind rTNFci continued to de-
crease for at least 4 h after a 1-h exposure to colchicine, by which time binding ca-
pacity had decreased 75%. 18 h after the 1-h exposure to colchicine, the capacity
ofthecells tobind rTNFuwasstill suppressed by 46%. Nocodazole binds reversibly
to tubulin (26); its effect on binding of rTNFa was 50% reversed by 1 h after its
removal.
Effect ofAntibody Against Murine TNF-a .
￿
Since macrophages secrete TNFa, it
was possible that MTdepolymerizing agents downregulated TNFaRbytriggering
endogenous TNFcirelease, leadingtointernalizationofligand-receptorcomplexes.
To test this, we made use ofa neutralizing antiserum(15E) against murine TNFa.
When present during the pretreatment of the cells with colchicine or nocodazole,
15E (sufficient to neutralize 1000 U/ml TNFa) did not prevent the subsequent de-
crease in ability ofthe cells to bind exogenous rTNFci (Table II). As a positive con-
TABLE I
Effect of Cytoskeleton Disrupting Agents on TNF-ceR or IFN-yR
FIGURE 2. Concentration-
dependent inhibition of 's51-
rTNRcx binding to macrophages
by preincubation with different
MT depolymerizing agents. in-
dicated concentrations of vin-
cristine (/), vinblastine ("),
colchicine ("), nocodazole (O),
podophyllotoxin (21), S-lumicol-
chicine (p), or .y-lumicolchi-
cine (*) were incubated with
macrophages for 1 h at 37°C in
the absence (A) or presence (B)
of 0.1% DMSO, used as a ve-
hicle for the water-insoluble
agents. The binding assay was
then performed at 4°C. The
results are representative of
five separate experiments, and
are means for triplicates (SEM
<5%).
' Each reagent was incubated with macrophages at 37°C for 1 h before the TNF-01R assay.
t Means t SE for triplicates from one of three similar experiments.
S Numbers in parentheses represent percent of control .
Reagents' Concentration
Specific
rTNF-a
bindingt by
rIFN-.y
cpm
- - 967 t 22 (100)S 991 t 84 (100)
Cytochalasin B 5 ug/ml 994 t 50 (103) ND
Dihydrocytochalasin B 5 Ftg/ml 946 t 19(98) ND
Cytochalasin E 5 pg/ml 816 t 57 (84) ND
Colchicine 10 ,UM 470 t 25 (49) 1,011 t 74 (102)
Nocodazole 10 AM 399 t 17 (41) 971 t 97 (98)E
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trol, in studies to be reported elsewhere (Ding, A. H., F Porteu, E. Sanchez, and
C. E Nathan, manuscript submitted forpublication), antibody 15E did blockdown-
regulation ofTNFaR in responseto a drugthat elicits TNFarelease (not shown).
Role ofthe Cyclooxygenase Pathway.
￿
Colchicine has been reported to induce the syn-
thesis ofcyclooxygenase products, leading to an increase in the intracellular level
ofCAMP (27, 28). To testwhetherthis pathwaywas involved inthecolchicine-induced
downregulation of TNFciR, macrophages were exposed to PGEI or dibutyryl-
cAMP, a lipid soluble analog of cAMP, for 1 h at 37°C, and then the binding of
1211-rTNFa was assessed. Neither of these agents decreased 1211-rTNFa binding
(Table III). In fact, high concentrations of PGEI or dibutyryl-CAMP had the op-
posite effect. Moreover, the cyclooxygenase inhibitors indomethacin (10-7 to 10-1 M),
ibuprofen (10' to 10-5 M), and acetylsalicylic acid (10-5 to 10-3 M) did not pre-
vent colchicine-induced downregulation of TNFaR (data not shown).
Role ofLPS .
￿
Since TNFaR of macrophages and endothelial cells can be down-
regulated by traces of LPS (10), a common contaminant of commercial reagents,
the LPS content ofall the MTdepolymerizing agents used in this study was deter-
TABLE II
Effect of Antiserum Against TNF-a on Colchicine and Nocodazole Action
' Means t SE for triplicates from one of four similar experiments.
t Diluted 1 :640.
FIGURE 3.
￿
RecoveryofTNF-a
binding sites on macrophages
after pulsing for 1 h at 37°C
with 10 AM colchicine (O) or
3 AM Ncodazole (A). Thetime
represents the duration between
addition ofdrugs and the start
ofthe binding assay. The results
are means t SE oftriplicates.
Where error bars are not seen,
they fall within the symbols.
Reagents Specific binding' Percent inhibition
cpm
Preimmune serums 907 t 20 -
+ 10 AM colchicine 397 t 23 56.2
+ 10 AM Noodazole 323 t 66 66.6
Antiserum 15Et 994 t 47 -
+ 10 AM colchicine 411 t 42 58.7
+ 10 pM Noodazole 392 t 13 60.6720
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TABLE III
Effect of PGEi and Dibutyryl-cAMP on TNF-aR
Reagents`
￿
Specific bindingl
cpm
880 t 52
PGEI
10-9 M
￿
734 t 34
10-e M
￿
881 f 68
10-7 M
￿
1,244 t 118
Dibutyryl-cAMP
10-6 M
￿
874 t 108
10-5 M
￿
951 f 167
10-4 M
￿
1,045 t 129
' Incubated with macrophages at 37°C for 1 h before the binding assay.
X Means t SE for triplicates from one of three similar experiments.
mined. At the concentrations ofdrugs used, the LPS content was <10 pg/ml, i.e.,
below the minimum effective concentration ofLPS (10). Moreover, as assessed by
immunofluorescence microscopy, the MT network remained intact in LPS-treated
macrophages, even though MT disappeared in macrophages treated with MT
depolymerizing agents (not shown). Thus the effect ofMTdepolymerizing agents
on TNFaR was not due to LPS, and the effect of LPS on TNFceR was not due
to depolymerization of MT
Effect ofCycloheximide.
￿
With a human myosarcoma cellline, inhibition ofprotein
synthesis with cycloheximide resulted in decreased surface expression ofTNFaR
with a half-life of 2 h (29). This suggested that TNFciR on the myosarcoma cells
turned over in the absence ofligand, perhaps by internalization, and that de novo
protein synthesis was necessary for replacement ofTNFciR on the cell surface. If
a similar situation existed in macrophages, then MTdepolymerizing agents might
reduce binding ofrTNFa by interfering with the ability ofthe cell to replace TNF
aR as TNFciR were lost from the cell surface. According to this hypothesis, cyclo-
heximide should inhibit binding ofrTNFa to a similar extent and with a similar
time course as colchicine. As shown in Fig. 4, this was the case. Exposure ofmacro-
phages to 10 hg/ml ofcycloheximide at 37°C resulted in 50% reductionofTNFaR
in 60 min in the absence of added ligand. The effect of colchicine on IFN--yR, a
receptor known to be insensitive to cycloheximide (30), was tested under the same
conditions. BindingofrIFN-y was not affected bycolchicine(Fig. 4). This suggested
that the effects of colchicine and cycloheximide on TNFaR did not result from
nonspecific toxicity, and that in the absence of exogenous ligand, TNFaR turns
over on the macrophage surface more quickly than IFN--yR.
Inhibition ofTNF-a-mediated Macrophage Activation by Colchicine.
￿
We next asked if
downregulation ofTNFciRby colchicine orcycloheximidewould affect TNFa-medi-
ated macrophage activation. Resident macrophages were pulsed for 1 hat 37°C with
mediumalone, colchicine, orcycloheximide. As an additionalcontrol, some macro-
phages were pulsed with(3-lumicolchicine. Afterremoval ofthese reagents, cellswere
incubated with increasing amounts of rTNFa for 48 h at 37 °C, washed, and ex-0
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posed to PMA to test their capacity to release H202 (31). Fig. 5 shows that pulsing
with cycloheximide or colchicine, but not (3-lumicolchicine, blunted the response
of macrophages to rTNF-a.
Elect ofColchicine on TNF-ciR ofHuman Endothelial Cells and PMN.
￿
The interac-
tion of PMN with endothelium plays a central role in the development of inflamma-
tion, and can be regulated by TNFa (32). We therefore examined the effect of MT
depolymerizing agents on TNF-ciR in human endothelial cells and PMN. As shown
in Figs. 6 and 7, 1-h treatment with colchicine or nocodazole resulted in a 38-47%
downregulation ofTNFotR in endothelial cells, while (3-lumicolchicine had no effect.
The concentration-response curves and kinetics of the effect of these agents on en-
dothelial cells matched those for mouse macrophages, and the Scatchard plots were
almost the same (Fig. 6, inset). Consistent with these findings, endothelial cells also
responded to cycloheximide with decreased 125I-rTNFa binding (Fig. 7). However,
no changes were found in TNFciR when human PMNs in suspension were exposed
for 1 h to either 10 gM colchicine or 10 FAg/ml cycloheximide (not shown).
Discussion
Incubation of macrophages or endothelial cells with any one of five MT depoly-
merizing agents in micromolar concentrations at 37oC resulted in a concentration-
dependent downregulation ofsurface TNFotR. As a consequence, macrophages ex-
posed to MTdepolymerizing agents became refractory to TNFci, a rare example
600
400
200
0
0 .025 .25 2.5 25
[TNFa) (ng/ml)
DING ET AL.
￿
721
FIGURE 4.
￿
Time course ofcolchicine- andcycloheximide-induced
TNF-ciR downregulation. Cells were incubated with 10 AM col-
chicine(0, A) or 10 Ag/mlcycloheximide (O, A) at 37oC forthe
time indicatedfollowed by the iTNFci (0, O) or the rIFN-.y (A,
A) binding assay. The results are expressed as a percent of the
specific binding seen with cells treated with medium alone, and
are means of triplicates (SEM <6%).
FIGURE 5.
￿
Inhibition of TNFa induced H202 re-
leaseby colchicine andcycloheximide. Resident mac-
rophages were pulsed for 1 h at 37oC with medium
(O), 10 AM colchicine (A), 10 /~g/ml of cyclohexi-
mide (0), or 10 AM fl-lumicolchicine (A). After
removalofdrugs, indicatedconcentrations of rTNFa
were added, and incubatedwith cells foran additional
48 h at 37oC in a 5% C02/957o airincubator. Then
H202 release wasdetermined in thepresence of 100
ng/ml of PMA. The results are means t SE for
triplicates.722
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FIGURE 6. Decreased TNF-
aR on humanendothelial cells
aftertreatmentwith colchicine.
Human endothelial cells were
pretreated with (A) or without
(O) 10 AM colchicine for 1 hat
37°C. Other conditions were
thesame as thelegend forFig. 1.
of inhibition of macrophage activation in vitro by a pharmacological agent in clin-
ical use.
The five effective agents belong to four structurally distinct classes; the only action
they are known to share is the ability to depolymerize MT. Inactive isomers of col-
chicinewere ineffective, as were microfilament-destabilizing cytochalasins. The spectra
of biologic effects of the drugs, theireffectiveconcentrations, and the relative revers-
ibility oftheiractions provide strong evidence that MT disassembly was responsible
for the observed downregulation of TNFaR.
FIGURE 7.
￿
Effect of drugs on TNRaR of human en-
dothelial cells.Confluentmonolayers ofendothelial cells were
incubated with medium alone, 10 AM nocodazole, 10 AM
colchicine, 10 PM /3-lumicolchicine, or 10 pg/mlcyclohexi-
mide for 1 h at 37 °C before the binding assay. The results
are means t SE for triplicates.DING ET AL.
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Several mechanisms might have been at work: competition by the MT
depolymerizing agents with 1211-rTNFa for its receptor; triggering ofthe release of
endogenous TNFac, followed by ligand-induced receptor downregulation; activa-
tion of protein kinase A via elevation ofintracellular cAMP; internalization trig-
gered by LPS contaminating the reagents (10); decrease of TNFctR synthesis; or
impairment oftransport ofnewly synthesized TNFuR to the plasma membrane.
Our data exclude the first four explanations but are consistent with either of the
last two. We could not distinguish whether the effect ofcolchicine on TNFaR was
due to inhibition ofTNFciR synthesis, interference with transport ofTNFaR to
the plasma membrane, or both. The question can only be answered when specific
antibodies and cDNA probes for TNFciR become available.
It has been suggested that MTcan affect polyribosome stability (33) and mRNA
levels (34). Macrophage and endothelial cell surface TNFaR declined as rapidly
after exposure to cycloheximide, an inhibitorofprotein synthesis, as they did after
exposure to colchicine. Surfacereceptors foranothermacrophage-activatingcytokine,
IFN-yR, were insensitive bothto cycloheximide andto colchicine overthesametime
interval. With another phagocyte, PMN, TNFciR were insensitive both to cyclo-
heximide and to colchicine, consistent with the limited protein synthetic capacity
ofPMN. Thus, in different celltypes, depolymerization ofcytoplasmic MTappeared
to have an impact on the turnover of TNFaR similar to that of interrupting the
synthesis of TNFceR.
MT are required for the transport of several kinds ofhormone receptors to the
plasma membrane. Colchicine prevented the recycling of insulin receptors to the
plasma membrane in rat hepatocytes after treatment with high concentrations of
insulin (35). Likewise, colchicine inhibitedtherecovery ofcardiac myocyte /3-adrenergic
receptors after their downregulation by an agonist (36). MT were required for ap-
ical surfaceexpression ofa plasma membrane protein ofunknown function in intes-
tinal epithelialcells(37). Finally, MTdepolymerizing agents interfered withthe secre-
tion ofa variety of proteins and peptides, including insulin (38), very low density
lipoproteins (39, 40), fibroblast growth factor (41), lysosomal enzymes (42), and
thyroxine (43). In contrast to the studies cited above with insulin receptors and ad-
renergicreceptors, downregulation ofTNFciRbycolchicine wasdemonstrable without
massiveligand-induced internalizationofthe receptors. Thisprobably reflected rapid
constitutive turnoverofTNFaR on macrophages andendothelial cells. In contrast
to cycloheximide, none ofthe MTdepolymerizing agents tested appeared to down-
regulate TNFuR completely, suggesting that expression of a portion of nascent
TNFuR does not depend on the MT network. Asimilar observation was made for
insulin receptors (35).
Emigration ofleukocytes across the endothelium is a critical aspect ofinflamma-
tion. TNF-ci can play an important role in this process (32), andcan induce macro-
phages and endothelial cells in such sites to release other inflammatory mediators,
such as IL-1, IL-6, neutrophil activating peptides, eicosanoids, and reactive oxygen
and nitrogen intermediates (18, 44-48). It is possible that the effects of MT
depolymerizing agents seen here with macrophages and endothelial cells may also
be exerted on some other types ofcells on which TNFa has potentially important
actions, including synovial cells (49) and lymphocytes (50). Thus, the downregula-
tionofTNFaR byMTdepolymerizing agents may contributeto theirantiinflamma-
tory effects.724
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Ifpharmacologiccompoundsthatdepolymerize MTcan modulate TNFaR, per-
haps endogenous signals that affect MTfunction can also affect TNFaR. The poly-
merization state ofMTis sensitive to the intracellular concentrationofcalcium (51).
It is also tightly controlled by MT-associated proteins, whose functions, inturn, are
regulated bykinases (52-56). Ourfindings raisethe possibility that certainhormones
or cytokines could modulate the expression ofreceptors for the same or other hor-
mones or cytokines through the interaction ofsecond messenger systems with the
MT network.
Summary
Exposure ofmurine andhumanmacrophages and human umbilical veinendothelial
cellsto micromolar concentrations offive microtubule (MT)-depolymerizing agents
(colchicine, nocodazole, podophyllotoxin, vincristine, and vinblastine) resulted in
a loss ofbinding sites for iodinated TNFa. The reduction amounted to 40-60%
by 1 h and N75% by 2-4 h. In 1 h, specific binding was reduced 50% by 0.1-5 ,UM
ofthese drugs at 37°C, but not at 4°C. Inactive isomers ofcolchicine were ineffec-
tive, as were microfilament-destabilizing cytochalasins. The active agents did not
compete with TNFaR for binding. Antiserum against TNFa did not neutralize
the effect of colchicine and nocodazole. PGEi and dibutyryl-CAMP could not
mimic, andcyclooxygenase inhibitors could not preventthedrug effects. All thebinding
sites were regenerated within 3 h after removal of nocodazole, which binds tubulin
reversibly, whereas little recovery was found even 18 h after the removal of colchi-
cine, which bindstubulin irreversibly. These findingssuggested that MT disassembly
was responsible forthe observed downregulation ofTNFciR. Theprotein synthesis
inhibitor cycloheximide inhibited binding of TNFci to a similar extent and with
a similar time course as colchicine in the absence of added ligand. Neither drug
affected binding ofIFN-y to macrophages, nor binding ofTNFU to human poly-
morphonuclear leukocytes. Thus, an intact MT network appears to be important
inmaintenanceofthe steady stateofTNFciR on those cellsinwhich TNFaR turns
over rapidly in the absence of ligand. The andinflammatory actions of MT-
depolymerizing agents may result in part from their interference with the ability
of such cells to respond to TNF-a.
WethankGenentech for reagents, andDr. E. Jaffeforhuman umbilicalveinendothelialcells.
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